2022 Fiscal Year Final Research Report
Development of new drugs and elucidation of immunity to cure all chronic myeloid leukemia patients
| Project/Area Number |
20K08756
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
|---|
| Research Institution | Saga University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
安藤 寿彦 佐賀大学, 医学部, 准教授 (30363097)
服部 奈緒子 国立研究開発法人国立がん研究センター, 研究所, 研究員 (30611090)
久保田 寧 埼玉医科大学, 医学部, 教授 (60570413)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 慢性骨髄性白血病 / チロシンキナーゼ / 治療不要寛解 / メチル化 |
|---|
| Outline of Final Research Achievements |
OR-2100, a novel orally available demethylating agent, was found to be effective against chronic myeloid leukemia (CML) cells and also against CML stem cells that cause relapse (Cancer Lett 2022). In a study of patients at Saga University, we found that NK cell immunity was mainly responsible for the decrease in CML cells when taking TKIs, and T cell immunity was important for the maintenance of treatment free remission (TFR) (Mol Cancer Ther 2021). Using samples from three TKI stop clinical trial participants, we re-examined the genetic polymorphisms of NK cell KIR and HLA and determined the importance of these combinations for TFR (manuscript in submission).
|
| Free Research Field |
血液内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
CMLは TKIによって、ほぼ死なない病気にはなったが、長期の服用による有害事象や高コストが問題になってきた。今回の研究成果は、より多くのCML患者において、TKIを安全に中止することを可能にすると期待される。本成果は、CML患者個人の QOLを高めるだけでなく、医療経済にとっても有益な情報を与えるものである。
|
